“To have the opportunity to test for the more common EGFR mutations at the same time is highly clinically relevant for us.” Simultaneous tests and multiple detections The dPCR technology that ...

Activating mutations in EGFR are characteristic of patients with ... While this study was designed to test non-inferiority of gefitinib as measured by PFS, it also included a pre-defined threshold ...

If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.

For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...